Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?

Value in Health

Volumn 22, Issue 1, 2019, Pages 99-103

  Culyer, Anthony J ^a   Chalkidou, Kalipso ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

cost benefit analysis; cost effectiveness analysis; universal health coverage

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISABILITY-ADJUSTED LIFE YEAR; ECONOMICS; HEALTH INSURANCE; INVESTMENT; MIDDLE INCOME COUNTRY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; WELFARE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DISABILITY; ECONOMIC MODEL; HEALTH CARE COST; HEALTH STATUS INDICATOR; HUMAN; PUBLIC OPINION; QUALITY OF LIFE; SOCIAL WELFARE;

COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH STATUS INDICATORS; HUMANS; INVESTMENTS; MODELS, ECONOMIC; PUBLIC OPINION; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SOCIAL WELFARE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNIVERSAL HEALTH INSURANCE;

EID: 85050373654     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2018.06.005     Document Type: Article

References (26)

1. Office of Technology Assessment. The implications of cost-effectiveness analysis of medical technology. 1980. Available from: https://catalog.hathitrust.org/Record/000771079. [Accessed June, 2018].
2. Canadian Coordinating Office for Health Technology Assessment. Canadian Guidelines for Economic Evaluation of Pharmaceuticals. 1994, Canadian Coordinating Office for Health Technology Assessment, Ottawa, ON.
3. Drummond, M.F., Stoddart, G.L., Torrance, G.W., Methods for the Economic Evaluation of Health Care Programmes. 1987, Oxford University Press, Oxford, UK.
4. Gold, M.R., Cost-Effectiveness in Health and Medicine. 1996, Oxford University Press, New York, NY.
5. World Health Organization. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. 2003, World Health Organization, Geneva, Switzerland, 289–312.
6. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. 2004, National Institute for Health and Care Excellence, London.
7. Wilkinson, T., Sculpher, M.J., Claxton, K., et al. The International Decision Support Initiative Reference Case for economic evaluation: an aid to thought. Value Health 19 (2016), 921–928.
8. International Decision Support Initiative. iDSI reference case for economic evaluation. Available from: http://www.idsihealth.org/resource-items/idsi-reference-case-for-economic-evaluation/. [Accessed May 11, 2018].
9. Santatiwongchai, B., Chantarastapornchit, V., Wilkinson, T., et al. Methodological variation in economic evaluations conducted in low- and middle-income countries: information for reference case development. PLoS One, 10, 2015, e0123853.
10. Robinson, L.A., Hammitt, J.K., Benefit-cost analysis in global health. January SSRN Electronic J, 2017, 10.2139/ssrn.2952014.
11. Sugden R, Williams AH. The principles of practical cost-benefit analysis. 1978. Available from: https://global.oup.com/academic/product/the-principles-of-practical-cost-benefit-analysis-9780198770411?cc=gb&lang=en&. [Accessed May 11, 2018].
12. Gaertner, W., Amartya Sen: Capability and well-being. Nussbaum, M., Sen, A., (eds.) The Quality of Life, 1993, Clarendon Press, Oxford, UK, 62–66.
13. Adler, M.D., Posner, E.A., New Foundations of Cost-Benefit Analysis. 2006, Harvard University Press, Cambridge, MA.
14. Brouwer, W.B.F., Culyer, A.J., van Exel, N.J.A., Rutten, F.F.H., Welfarism vs. extra-welfarism. J Health Econ 27 (2008), 325–338.
15. Garber, A.M., Phelps, C.E., Economic foundations of cost-effectiveness analysis. J Health Econ 16 (1997), 1–31.
16. Donaldson, C., The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?. Pharmacoeconomics 13 (1998), 389–396.
17. Gafni, A., Economic evaluation of health-care programmes: Is CEA better than CBA?. Environ Resour Econ 34 (2006), 407–418.
18. Brouwer, W.B., Koopmanschap, M.A., On the economic foundations of CEA. Ladies and gentlemen, take your positions!. J Health Econ 19 (2000), 439–459.
19. Torrance, G.W., Feeny, D., Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5 (1989), 559–575.
20. Neumann, P.J., Sanders, G.D., Cost-effectiveness analysis 2.0. N Engl J Med 376 (2017), 203–205.
21. Neumann, P.J., Should value frameworks take a “societal perspective”?. Health Aff Blog, 2017 https://www.healthaffairs.org/do/10.1377/hblog20170906.061833/full/. [Accessed September 2017].
22. Chalkidou K, Culyer AJ, Nemzoff C. Perspective in economic evaluations of health care interventions in low- and middle-income countries—one size does not fit all. 2018. Available from: www.cgdev.org. [Accessed May 14, 2018].
23. Claxton, K., Sculpher, M., Palmer, S., Culyer, A.J., Causes for concern: Is NICE failing to uphold its responsibilities to all NHS patients?. Health Econ 24 (2015), 1–7.
24. Thokala, P., Duenas, A., Multiple criteria decision analysis for health technology assessment. Value Health 15 (2012), 1172–1181.
25. Garrison, L.P., Neumann, P.J., Willke, R.J., et al. A health economics approach to US value assessment frameworks—summary and recommendations of the ISPOR Special Task Force Report-7. Value Health 21 (2018), 161–165.
26. International Decision Support Initiative. Cost-effectiveness thresholds. Available from: https://www.idsihealth.org/resource-items/cost-effectiveness-thresholds/. [Accessed May 14, 2018].